Loading clinical trials...

Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT00769145

Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery

The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing corneal transplantation.

Lead sponsor: University of Miami•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

RECRUITINGPhase 2/3

Corneal Crosslinking for Treatment of Corneal Neovascularization

NCT04787471 · Corneal Neovascularization

COMPLETEDPhase 2/3

Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

NCT00555594 · Corneal Neovascularization

UNKNOWN

Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.

NCT05659940 · Corneal Neovascularization, Neutrophils

COMPLETEDPhase 1

Topical Avastin for Treatment of Corneal Neovascularization

NCT00559936 · Corneal Neovascularization

TERMINATEDPhase 1/2

Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization

NCT02797704 · Corneal Neovascularization

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 11, 2017Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment5

Start dateOct 2008

Last updatedJul 11, 2017

Condition

Corneal Neovascularization

Locations shown

Bascom Palmer Eye Institute

Miami, Florida

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 11, 2017Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions